Efficacy of Hydroxyurea in Patients With Sickle Cell Anemia in a Low‐Income Country (Côte d’Ivoire)

Anemia · Published 2025-01-01 · DOI 10.1155/anem/3576890

Authors being retrieved — see the publisher record. https://doi.org/10.1155/anem/3576890

Abstract

Conclusion: Hydroxyurea has an important clinical benefit by reducing the incidence of vaso-occlusive events, infections, and transfusions, which translates into fewer hospitalizations. The main problem is that it is not accessible to most of our patients who live in poor socioeconomic conditions.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2025

Related articles